Anti-Thymocyte Globulin (ATG)

Anti-Thymocyte Globulin (ATG) is an immunosuppressive biologic agent composed of purified polyclonal antibodies against human T lymphocytes. It is used to reduce immune responses by depleting circulating T-cells and is commonly employed in organ transplantation and autoimmune hematological disorders.

✅ Approved & Common Indications

🌿 Prevention and Treatment of Acute Graft Rejection in Organ Transplantation

• Indicated as part of induction therapy to prevent acute rejection in kidney, liver, heart, and other solid organ transplants.
• Also used for treatment of steroid-resistant acute rejection episodes, especially in renal transplant recipients.

🌿 Aplastic Anemia

• Indicated for the treatment of severe aplastic anemia (SAA) in patients who are not candidates for hematopoietic stem cell transplantation (HSCT).
• Commonly used in combination with cyclosporine for immunosuppressive therapy in SAA.

🌿 Hematopoietic Stem Cell Transplantation (HSCT)

• Used in conditioning regimens prior to allogeneic HSCT to prevent graft-versus-host disease (GVHD) by depleting host T-cells.
• Also indicated to prevent graft rejection in mismatched or unrelated donor transplants.

🌿 Other Off-label/Supportive Uses (Specialist Discretion)

• Management of hemophagocytic lymphohistiocytosis (HLH)
• Treatment-resistant autoimmune disorders, such as lupus or myasthenia gravis (rare cases)
• Chronic graft-versus-host disease (cGVHD) in select transplant patients